全文获取类型
收费全文 | 10403篇 |
免费 | 664篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 122篇 |
儿科学 | 339篇 |
妇产科学 | 181篇 |
基础医学 | 1211篇 |
口腔科学 | 176篇 |
临床医学 | 853篇 |
内科学 | 2806篇 |
皮肤病学 | 140篇 |
神经病学 | 924篇 |
特种医学 | 379篇 |
外科学 | 1316篇 |
综合类 | 129篇 |
一般理论 | 9篇 |
预防医学 | 967篇 |
眼科学 | 226篇 |
药学 | 700篇 |
中国医学 | 18篇 |
肿瘤学 | 610篇 |
出版年
2023年 | 43篇 |
2022年 | 51篇 |
2021年 | 151篇 |
2020年 | 78篇 |
2019年 | 131篇 |
2018年 | 170篇 |
2017年 | 136篇 |
2016年 | 155篇 |
2015年 | 209篇 |
2014年 | 224篇 |
2013年 | 385篇 |
2012年 | 724篇 |
2011年 | 801篇 |
2010年 | 389篇 |
2009年 | 305篇 |
2008年 | 725篇 |
2007年 | 777篇 |
2006年 | 726篇 |
2005年 | 760篇 |
2004年 | 696篇 |
2003年 | 645篇 |
2002年 | 604篇 |
2001年 | 259篇 |
2000年 | 325篇 |
1999年 | 214篇 |
1998年 | 127篇 |
1997年 | 88篇 |
1996年 | 81篇 |
1995年 | 86篇 |
1994年 | 63篇 |
1993年 | 70篇 |
1992年 | 40篇 |
1991年 | 46篇 |
1990年 | 45篇 |
1989年 | 43篇 |
1988年 | 42篇 |
1987年 | 55篇 |
1986年 | 31篇 |
1985年 | 42篇 |
1984年 | 52篇 |
1983年 | 41篇 |
1982年 | 51篇 |
1981年 | 51篇 |
1980年 | 43篇 |
1979年 | 21篇 |
1978年 | 32篇 |
1977年 | 33篇 |
1976年 | 22篇 |
1975年 | 25篇 |
1973年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
A Ascari-Raccagni†‡ MG Righini† 《Journal of the European Academy of Dermatology and Venereology》2006,20(5):514-516
BACKGROUND: Repairing dorsal nasal defects is a frequent challenge for dermatologic surgeons, mainly due to the high frequency of basal cell carcinomas on this site. Obvious scars, mismatched skin and distortion of the nasal contour are the surgical hazards that must be avoided in these cases. AIM: Our aim was to perform surgery involving a simple flap in order to repair medium to large defects on the dorsal side of the nose. METHODS: The dorsal horizontal advancement flap was studied in 12 patients, in order to evaluate the benefits and limits of this surgical procedure. RESULTS: The resulting scars on most of our patients were well-camouflaged among their natural skin lines, and there was neither distortion of the alar contour nor the nostril. CONCLUSIONS: This flap is easy to perform and, in selected cases, provides an outstanding alternative to second-intention healing, full-thickness skin grafts, transposition, rotation and pedicle flaps. 相似文献
5.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献
6.
Posttraumatic stress disorder and associated risk factors in Canadian peacekeeping veterans with health-related disabilities. 总被引:2,自引:0,他引:2
OBJECTIVES: This study investigates posttraumatic stress disorder (PTSD) and its associated risk factors in a random, national, Canadian sample of United Nations peacekeeping veterans with service-related disabilities. METHODS: Participants included 1016 male veterans (age < 65 years) who served in the Canadian Forces from 1990 to 1999 and were selected from a larger random sample of 1968 veterans who voluntarily and anonymously completed a general health survey conducted by Veterans Affairs Canada in 1999. Survey instruments included the PTSD Checklist-Military Version (PCL-M), Center for Epidemiological Studies-Depression Scale (CES-D), and questionnaires regarding life events during the past year, current stressors, sociodemographic characteristics, and military history. RESULTS: We found that rates of probable PTSD (PCL-M score > 50) among veterans were 10.92% for veterans deployed once and 14.84% for those deployed more than once. The rates of probable clinical depression (CES-D score > 16) were 30.35% for veterans deployed once and 32.62% for those deployed more than once. We found that, in multivariate analyses, probable PTSD rates and PTSD severity were associated with younger age, single marital status, and deployment frequency. CONCLUSIONS: PTSD is an important health concern in the veteran population. Understanding such risk factors as younger age and unmarried status can help predict morbidity among trauma-exposed veterans. 相似文献
7.
8.
9.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
10.